TABLE 3.

Comparison of nonsynonymous pncA gene mutations with pyrazinamide resistance results based on Bactec MGIT 960

PZA susceptibilitya	No. of isolates with:		% sensitivity (95% CI)	% specificity (95% CI)	ROC-AUC (95% CI)
	pncA nonsynonymous mutations/deletions	pncA wild typeb or synonymous mutations
Overall, n = 878
Resistant	131	16	89.1 (83.05, 93.19)	99.3 (98.41, 99.71)	0.94 (0.925, 0.957)
Susceptible	5	726
MDR, n = 129
Resistant	37	2	94.9 (83.11, 98.58)	96.7 (90.65, 98.86)	0.96 (0.907, 0.985)
Susceptible	3	87
ODR, n = 271
Resistant	60	11	84.5 (74.35, 91.12)	99.0 (96.43, 99.73)	0.92 (0.878, 0.947)
Susceptible	2	198
DS, n = 478
Resistant	34	3	91.9 (78.70, 97.20)	100.0 (99.14, 100.00)	0.96 (0.938, 0.975)
Susceptible	0	441
Beijing family, n = 739
Resistant	122	14	89.7 (83.46, 93.77)	99.2 (98.07, 99.65)	0.94 (0.925, 0.960)
Susceptible	5	598
Non-Beijing family, n = 139
Resistant	9	2	81.8 (52.30, 94.86)	100.0 (97.09, 100.00)	0.91 (0.849, 0.951)
Susceptible	0	128
GY, n = 254
Resistant	36	8	81.8 (68.04, 90.49)	99.0 (96.59, 99.74)	0.90 (0.861, 0.938)
Susceptible	2	208
DQ, n = 216
Resistant	33	4	89.2 (75.29, 95.71)	98.3 (95.19, 99.43)	0.94 (0.897, 0.966)
Susceptible	3	176
GJ, n = 237
Resistant	36	2	94.7 (82.71, 98.54)	100.0 (98.11, 100.00)	0.97 (0.944, 0.990)
Susceptible	0	199
RO, n = 171
Resistant	26	2	92.9 (77.35, 98.02)	100.0 (97.38, 100.00)	0.96 (0.924, 0.987)
Susceptible	0	143

^aDS, drug susceptible to isoniazid, rifampin, ethambutol, and streptomycin; MDR, multidrug resistant; ODR, other first-line drug resistant; PZA, pyrazinamide.

^bWild type refers to the isolates without the identified mutation in the pncA gene.